Buijs Servaas, Krol Marieke, de Voer Gert
HealthCare Insights, Loodsboot 7, 3991 CJ, Houten, The Netherlands.
IQVIA, Herikerbergweg 314, 1101 CT, Amsterdam, The Netherlands.
J Comp Eff Res. 2018 May;7(5):453-462. doi: 10.2217/cer-2017-0077. Epub 2018 May 18.
To investigate the incidence and prevalence and healthcare costs of multiple sclerosis (MS) in the Netherlands by using healthcare claims data.
MATERIALS & METHODS: A claims database was analyzed including 26% of the Dutch population.
Average prevalence of MS in the Netherlands was 88 per 100,000 inhabitants (males 48, 127 females) and incidence nine per 100,000. Yearly per patient medication costs were highest in the year after the first MS claim and then decreased. Hospital costs were 30% higher in the first year of MS claims than after 3 years of MS claims. The patients often used co-medication, such as antidepressants and antibiotics.
Dutch incidence and cost estimates based on claims were consistent with previous estimates. Prevalence estimates were somewhat higher. Drug and hospital costs were highest shortly after the diagnosis. Healthcare consumption related to comorbidities was in-line with the previously reported comorbidity estimates.
利用医疗索赔数据调查荷兰多发性硬化症（MS）的发病率、患病率及医疗费用。
分析了一个包含26%荷兰人口的索赔数据库。
荷兰MS的平均患病率为每10万居民88例（男性48例，女性127例），发病率为每10万居民9例。每位患者每年的药物费用在首次MS索赔后的第一年最高，随后下降。MS索赔第一年的住院费用比索赔3年后高30%。患者经常使用辅助药物，如抗抑郁药和抗生素。
基于索赔的荷兰发病率和成本估计与先前估计一致。患病率估计略高。诊断后不久药物和住院费用最高。与合并症相关的医疗消费与先前报告的合并症估计相符。
